Free Trial

Palatin Technologies Q2 2023 Earnings Report

Palatin Technologies logo
$1.00 -0.02 (-1.96%)
As of 02/21/2025 04:10 PM Eastern

Palatin Technologies EPS Results

Actual EPS
-$0.91
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.38
One Year Ago EPS
-$1.34

Palatin Technologies Revenue Results

Actual Revenue
$1.76 million
Expected Revenue
$1.26 million
Beat/Miss
Beat by +$500.00 thousand
YoY Revenue Growth
N/A

Palatin Technologies Announcement Details

Quarter
Q2 2023
Time
Q4 2023 Earnings Release

Palatin Technologies Earnings Headlines

Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
Q2 2025 Palatin Technologies Inc Earnings Call
See More Palatin Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palatin Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palatin Technologies and other key companies, straight to your email.

About Palatin Technologies

Palatin Technologies (NYSEAMERICAN:PTN), a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

View Palatin Technologies Profile

More Earnings Resources from MarketBeat